Project Grant R21EY037445
Award Date
6/1/25
Completion Date
5/31/27
Dollars Obligated
$424K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
This federal Project Grant award of $679,159 from the National Eye Institute (NEI), under the NIH Vision Research program (CFDA 93.867), supports research to investigate the combined effects of aging and elevated intraocular pressure on the development of glaucoma and the retinal ganglion cell (RGC) transcriptome. The research aims to identify age- and glaucoma-specific transcriptomic changes, and determine how these changes are altered by in vivo transient epigenetic reprogramming using...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), will support research to investigate the cellular and synaptic mechanisms underlying changes in retinal ganglion cell (RGC) activity following optic nerve injury in mouse models of glaucoma. The $460,625 award, with a project period from September 30, 2024 to September 29, 2026, will enable researchers at Yale University to: (1) determine the underlying mechanisms responsible for...
This National Eye Institute (NEI) Vision Research (CFDA 93.867) Project Grant award of $387,428 supports research to investigate fundamental mechanisms driving optic nerve sensitivity to elevated intraocular pressure (IOP) in glaucoma. The 5-year project, led by the Research Foundation for the State University of New York (Upstate Medical Center), aims to determine how transient biomechanical strains on optic nerve head astrocytes may predispose them to glaucomatous dysfunction. The research...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research to investigate the role of cGMP signaling in glaucomatous neurodegeneration. The $526,841 award to Vanderbilt University Medical Center aims to elucidate how disrupted cGMP signaling in glaucoma impacts retinal astrocyte-vascular networks, leading to retinal ganglion cell (RGC) metabolic stress and axon degeneration. The research will utilize cell-specific...
This $618,088 Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) supports research at the University of Texas Medical Branch at Galveston to investigate the role of damaged mitochondrial DNA (mtDNA) and the DNA/RNA sensor ZBP1 in retinal ganglion cell degeneration and neurodegeneration associated with glaucoma. The project will leverage novel animal models and in vitro studies to explore how mtDNA acts as an immune factor, binding to ZBP1 and inducing signaling...
The National Eye Institute (NEI) awarded a $360,897 Project Grant (CFDA 93.867 Vision Research) to Human Cell Co, a for-profit biotechnology company, with a performance period from September 30, 2024 to August 31, 2025. The grant supports the development of a novel combination therapy for glaucoma, a leading cause of irreversible vision loss. Specifically, the funding will be used to determine if the combined application of a proprietary nerve growth factor (NGF) mutein, HC201, and oral...
This Project Grant award from the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) provides $246,000.00 in funding to The University of Texas Southwestern Medical Center to conduct research on the genetic basis and molecular mechanisms of early-onset glaucoma. The research will leverage a high-throughput and unbiased forward genetics pipeline to identify novel gene-phenotype associations related to this blinding disease. The project aims to advance the...
This National Eye Institute (NEI) Project Grant award, under the Vision Research federal grant program (CFDA 93.867), provides $2,260,440.00 in funding to The Leland Stanford Junior University to conduct research on compartmentalized cAMP signaling in reactive astrocytes. The research aims to establish the molecular, cellular, and transcriptional mechanisms that regulate neurotoxic and protective astrocyte reactivity in a mouse model of glaucoma. Key objectives include using single-cell RNA...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), will support research to investigate the molecular mechanisms underlying cell death caused by mutant myocilin misfolding in glaucoma. The $447,479 award to Georgia TECH Research Corp, which operates as the Office of Sponsored Programs, will fund a 5-year project to use a yeast model system to screen for gene targets and small molecule compounds that can rescue the cytotoxicity...
This federal Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) totaling $393,008 provides funding to the University of California, Davis (UC Davis) to conduct research on how the frog Xenopus laevis is able to successfully regenerate damaged retinal ganglion cell (RGC) axons and regain vision. The goal is to systematically study the intrinsic pathways and the role of myeloid cells in this regeneration process, with the aim of identifying potential therapeutic...